SutroVax, Inc.
SutroVax, Inc. is listed today as Vaxcyte, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2020 | $110 M | No. 4 | $50 to $250 million | equity | SEC | |
| May 2018 | $43 M | No. 3 | $10 to $50 million | equity, options | SEC | |
| Mar 2017 | $40 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jul 2015 | $13 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
SutroVax, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2020).
SEC Form D · Apr 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Apr 2020
That is all the official record says: SutroVax, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of SutroVax, Inc. are on record.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Abingworth LLP | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Longitude Capital Partners II, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Longitude Venture Partners II, L.P. | Venture capital | not stated | not stated | Held Series A, B, C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| TPG Group Holdings (SBS) Advisors, Inc. | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 23 investors.
Largest shareholders today
Institutions holding Vaxcyte, Inc. shares, as of Sep 30, 2026.
- FMR LLC$1.3 B14.20%
- Janus Henderson Group Ltd.$1.0 B11.32%
- T. Rowe Price Investment Management, Inc.$814 M9.03%
- BlackRock, Inc.$693 M7.69%
- Ra Capital Management, L.P.$653 M7.25%
- Wellington Management Group LLP$440 M4.89%
- Vanguard Capital Management LLC$374 M4.15%
- Vanguard Portfolio Management LLC$374 M4.15%
- State Street Corp$298 M3.31%
- Price T Rowe Associates Inc /MD/$201 M2.23%
- Deep Track Capital, LP$200 M2.22%
- Geode Capital Management, LLC$199 M2.21%
- Westfield Capital Management Co LP$187 M2.07%
- Kynam Capital Management, LP$148 M1.65%
- Goldman Sachs Group Inc$133 M1.47%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Grant E Pickering | Executive officer | Apr 2020 |
| James P Wassil | Executive officer | Apr 2020 |
| Jane P Wright-Mitchell | Executive officer | Apr 2020 |
| Jeff E Fairman | Executive officer | Apr 2020 |
| Durga P Bobba | Executive officer | Jun 2018 |
| Elaine P Sun | Executive officer | Jun 2018 |
| Ashish Khanna | Executive officer | Mar 2017 |
| Elaine Sun | Executive officer | Mar 2017 |
| Grant Pickering | Executive officer | Mar 2017 |
| Jeff Fairman | Executive officer | Mar 2017 |
| Ashish E Khanna | Executive officer | Jul 2015 |
| Grant E Pickering | Director | Apr 2020 |
| Heath J Lukatch | Director | Apr 2020 |
| Kurt P von Emster | Director | Apr 2020 |
| Moncef J Slaoui | Director | Apr 2020 |
| Patrick J Enright | Director | Apr 2020 |
| Patrick J Heron | Director | Apr 2020 |
| Peter J Hirth | Director | Apr 2020 |
| Rob J Hopfner | Director | Apr 2020 |
| William J Newell | Director | Apr 2020 |
| Patrick P Enright | Director | Jun 2018 |
| Patrick P Heron | Director | Jun 2018 |
| Grant Pickering | Director | Mar 2017 |
| Kurt von Emster | Director | Mar 2017 |
| Patrick Enright | Director | Mar 2017 |
| Patrick Heron | Director | Mar 2017 |
| Peter Hirth | Director | Mar 2017 |
| Tracy Saxton | Director | Mar 2017 |
| William Newell | Director | Mar 2017 |
| Kurt E von Emster | Director | Jul 2015 |
| Patrick E Enright | Director | Jul 2015 |
| Tracy E Saxton | Director | Jul 2015 |
| William E Newell | Director | Jul 2015 |
| Grant E Pickering | Promoter | Jul 2015 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.